Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Sells $48,414.22 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Allogene Therapeutics Stock Performance

ALLO traded down $0.04 during trading on Thursday, reaching $1.88. The company had a trading volume of 1,389,630 shares, compared to its average volume of 2,946,952. The firm’s 50-day simple moving average is $2.14 and its 200 day simple moving average is $2.52. Allogene Therapeutics, Inc. has a 12-month low of $1.78 and a 12-month high of $5.78. The company has a market cap of $394.18 million, a price-to-earnings ratio of -1.21 and a beta of 0.86.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ALLO. Piper Sandler decreased their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Allogene Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $9.73.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at approximately $6,349,000. Lynx1 Capital Management LP acquired a new position in shares of Allogene Therapeutics during the 2nd quarter worth $5,192,000. Renaissance Technologies LLC raised its holdings in shares of Allogene Therapeutics by 340.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after purchasing an additional 1,351,055 shares in the last quarter. Zacks Investment Management bought a new position in shares of Allogene Therapeutics during the 3rd quarter valued at $1,446,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Allogene Therapeutics by 24.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock valued at $5,944,000 after purchasing an additional 507,021 shares during the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).